🇺🇸

US SEC Filing Intelligence

· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — March 27, 2026

The USA Bankruptcy & Insolvency intelligence stream highlights a single critical filing from Iterum Therapeutics plc, signaling imminent corporate dissolution amid acute financial distress. Key drivers include severely limited cash resources, ongoing Nasdaq listing non-compliance, failed acquisition discussions for sulopenem, and modest ORLYNVAH sales insufficient to cover high operating costs, with no period-over-period data indicating any positive revenue growth or margin expansion. The Irish High Court petition for winding up, filed March 27, 2026, led to the appointment of Joint Provisional Liquidators Damien Murran and Jennifer McMahon, who may withdraw ORLYNVAH from the U.S. market and oversee subsidiary wind-downs. This development carries maximum materiality (10/10) and uniformly negative sentiment, implying near-total equity value destruction, potential delisting, and disrupted commercialization efforts. Portfolio-level implications point to elevated insolvency risks in small-cap biotech, where cash burn outpaces revenue generation, warranting immediate short positioning or avoidance.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 27, 2026

Across 50 SEC filings on USA Board Room Changes dated March 27, 2026, the dominant theme is elevated executive and board turnover, with 22 resignations/terminations/non-re-elections (44%), 18 appointments/promotions (36%), and 10 compensation/plan updates (20%), signaling transitional instability particularly in biotech/pharma (12/50 filings) and small-caps. Sentiment skews neutral (80%), with positive tones on strategic hires (e.g., Rumble CFO from Intel, Sturm Ruger CFO transition) and mixed/negative on sudden exits (e.g., Cue Biopharma CEO, Nuwellis director disputes). No explicit YoY/QoQ financial deteriorations noted, but interim leadership in 8 cases (e.g., One World, Reed's, Genesco) flags potential execution risks amid bonus plans tied to EBITDA/FFO targets in 5 firms. Activist-driven changes at NCL (board expansion to 9, 4 resign/5 appoint) highlight governance shakeups. Portfolio implications: Monitor small-cap biotechs for volatility; positive hires suggest growth conviction in tech/industrials. Overall, 14 high-materiality events (7-9/10) warrant near-term scrutiny for stock catalysts around AGMs.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — March 27, 2026

The 18 filings reveal a dominant SPAC ecosystem frenzy with 15/18 documents from blank check companies, highlighting IPO completions (BHAV $102M total proceeds, Blue Water IV $134.25M, TRG partial over-allotment to $206.32M total), trust extensions (Ribbon $125K 1-month, Rising Dragon $50K note, IB to Sep 2026, International Media 16th extension to May 2026, Columbus $50K to Apr 2026), and leadership churn (resignations/appointments at AltEnergy, Charlton Aria, Goldenstone). Actual M&A progress includes ETHZilla's $150M 5-year revolving loan purchase commitment (initial $1.44M acquired), Contango ORE's completed 50/50 merger with Dolly Varden yielding >$100M cash/minimal debt, Pelican Holdco's pending merger with loss-making March GL (going concern doubts, $1.67M assets), and Drugs Made's sponsor transition for AI/cyber target with $500K funding commitment. No broad period-over-period trends due to non-operating status of most SPACs, but aggregate fresh trust deposits exceed $500M from IPOs/extensions, signaling robust dry powder for de-SPAC deals into Q2 2026. Neutral-to-positive sentiment prevails (12/18 positive/neutral), with mixed cases tied to distress; portfolio implication is heightened M&A liquidity but execution risks from extensions/churn.

18 high priority 18 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 27, 2026

Overnight SEC filings from March 26-27, 2026, feature 50 documents dominated by proxy statements (DEFA14A/DEF 14A) for May 2026 AGMs across airlines, oil, pharma, and biotech, signaling routine governance but with embedded FY2025 highlights showing mixed performance. Period-over-period trends reveal revenue growth in 8/15 10-Ks (e.g., Sportradar +17% YoY, BitGo +424% YoY, Apollo investment income +1,540% YoY) offset by declines in 7/15 (Luminar -12% YoY, Phunware -19.9% YoY, SpringBig -7.4% YoY), with margin expansions in Indivior (+500 bps to 35%) and Sportradar (+480 bps profit margin) but compressions elsewhere. Biotech shines with clinical wins (Kodiak Phase 3 success, Nurix 83% ORR), while credit funds maintain stable leverage (0.57x-0.82x) and distributions; SPACs/BLANKS show IPO completions and amendments amid no revenues but trust growth. Capital allocation leans shareholder-friendly (Indivior $400M buyback, Oaktree $0.16/share distro, News Corp $1B repurchase), but management churn (resignations at One World, AltEnergy) raises flags. Portfolio-level: Energy/oil mixed (Murphy +3% prod YoY), tech/autonomy challenged (Luminar assets -64% YoY), potential M&A (Brown-Forman/Pernod) as top catalyst. Actionable: Favor biotech/credit longs pre-AGMs, monitor SPAC redemptions.

28 high priority 22 medium 50 total filings
· daily

Biotech Small-Cap Approvals — March 26, 2026

Denali Therapeutics' FDA approval of NME orphan drug TIVIDENOFUSP ALFA-EKNM marks the sole bullish signal in a period dominated by 3 neutral generic ANDA approvals (75% of records). This divergence highlights innovative biotech upside for Denali amid routine generic expansions by Aurobindo, Macleods, and Rising. Prioritize Denali for premium pricing potential; generics offer limited alpha due to pricing pressures.

4 total filings
· daily

NME Blockbuster Approvals — March 26, 2026

Denali Therapeutics secured FDA approval for TIVIDENOFUSP ALFA-EKNM (AVLAYAH), a priority-reviewed NME orphan drug (BLA 761485, approved 2026-03-24), delivering a bullish catalyst for near-term revenue via commercial launch and exclusivity benefits. This sole blockbuster in the NME stream underscores regulatory favoritism for orphan designations but highlights data gaps in indication and competition. Institutional investors should prioritize Denali for growth exposure while monitoring label details to quantify market potential.

1 total filings
· daily

New Drug Approvals (Original) — March 26, 2026

One priority-reviewed NME BLA approval for Denali Therapeutics signals bullish biotech momentum with orphan exclusivity potential, dominating the period's 4 approvals. Three standard ANDA generics for Aurobindo Pharma, Macleods Pharms, and Rising add neutral volume but face pricing pressures without designations. Focus institutional capital on Denali for near-term launch upside while viewing generics as low-margin filler.

4 total filings
· daily

HHS & Healthcare Contracts Intelligence — March 26, 2026

HHS BARDA awarded $288M in two large biotech/health R&D contracts in late 2023, providing 4-6 year revenue visibility amid sustained pandemic preparedness funding. Bullish signal for corporate PPD Development LP ($126M, $23M outlayed, to 2029) contrasts neutral nonprofit ATI ($161M, minimal $240k outlay, to 2027), limiting broad equity upside. Monitor outlay acceleration and COVID priorities for execution risks in early-stage, long-duration awards.

2 total filings
· daily

New Federal Contractors — March 26, 2026

HHS dominates with $792.8M in health R&D obligations (45% of total), signaling multi-year federal priority in tobacco studies, biotech, and COVID vaccine tech through 2029. Bullish signals on three corporate/SDVOSB contractors (Westat, AATD, PPD) offer $1.2B+ potential via options/outlays, contrasting neutral nonprofits (Acacia, Advanced Tech). VA IT award to SDVOSB AATD highlights small biz set-aside leverage amid $1.76B total obligations.

5 total filings
· daily

Significant Contract Modifications ($10M+) — March 26, 2026

HHS dominates with $793M (45%) in health R&D contracts through 2029, signaling sustained federal priority on tobacco/health studies, biotech, and COVID immunogenicity amid $1.76B total modifications. Bullish signals for for-profit contractors Westat, AATD, and PPD highlight revenue visibility from high outlays ($122M-$213M disbursed) and options upside ($423M-$960M potential). Neutral nonprofits (Acacia, Advanced Tech) limit equity plays but underscore stable funding in refugee legal and BARDA biotech.

5 total filings
· daily

Contract Deobligations Alert — March 26, 2026

Deobligations alert reveals $1.76B in federal contracts with 3 bullish signals dominating (60% of records, $770M obligations) in HHS health R&D and VA IT services, signaling sustained funding flows. Neutral nonprofit awards ($993M) limit direct equity upside but underscore stable program spending in refugee legal aid and biotech. Investors should prioritize corporates/SDVOSBs with unexercised options (~$607M potential) amid long-term visibility to 2029.

5 total filings
· daily

Contract Option Exercises — March 26, 2026

Five contract option exercises totaling $1.76B highlight bullish signals for for-profit health R&D and VA IT providers (Westat, AATD LLC, PPD), with $770M obligated and strong outlays signaling revenue visibility through 2029. Neutral signals dominate two large nonprofit awards (Acacia, Advanced Technology International) totaling $993M, limiting direct equity upside. Investors should prioritize for-profit entities with unexercised options (~$707M potential) amid HHS/BARDA concentration (45% of value) in long-term R&D.

5 total filings
· daily

All HHS Contracts — March 26, 2026

HHS awarded $793M in health R&D contracts dominated by Westat's $505M PATH Study renewal (64% of total), signaling sustained federal commitment to longitudinal public health research through 2028. BARDA's $287M in biotech/COVID R&D awards to PPD and ATI provide multi-year visibility to 2029, though nonprofit ATI limits equity upside. Bullish for corporate contractors with optionality exceeding $1.2B potential value, but long tenors introduce funding risks amid shifting priorities.

3 total filings
· daily

Mega Contracts Monitor ($100M+) — March 26, 2026

HHS dominates with $792M in health R&D awards (PATH Study, biotech, COVID vaccines), signaling bullish multi-year funding visibility to 2029 for corporate contractors like Westat and PPD amid 3 bullish signals out of 5 contracts totaling $1.76B. DOI's $832M legal services contract for unaccompanied children underscores stable social services funding but neutral equity impact as a nonprofit. VA's $138M IT award highlights SDVOSB opportunities in federal tech services through 2026.

5 total filings
· daily

High-Value Federal Grants ($5M+) — March 26, 2026

High-value federal grants totaling $1.76B highlight sustained HHS funding for health R&D (PATH Study, BARDA biotech/COVID assays) and VA IT services, with 3 bullish signals for corporate/SDVOSB recipients providing multi-year revenue visibility through 2029. Neutral signals dominate nonprofits in legal/refugee services and early-stage biotech, limiting direct equity upside. Investors should prioritize for-profit health R&D and VA IT plays amid high outlay rates (e.g., 94% in Acacia, 88% in AATD) and unexercised options exceeding $700M across contracts.

5 total filings
· daily

General Federal Contracts — March 26, 2026

HHS dominates with $792M (45%) in health R&D contracts signaling bullish long-term revenue for Westat and PPD through 2028-2029, while DOI's $832M legal services award to nonprofit Acacia underscores stable migrant support funding. VA's $138M IT delivery order highlights SDVOSB opportunities with $423M potential upside for AATD. Overall $1.76B in awards emphasizes health/services durability but limits direct equity plays via nonprofits.

5 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 26, 2026

Across 13 filings from the S&P 500 Technology stream (with some cross-sector inclusions), dominant themes include neutral proxy statements for upcoming AGMs, mixed financial results highlighting cost discipline amid revenue softness, and selective growth in reserves/operations. Period-over-period trends show revenue declines averaging -5% YoY in reporting companies (e.g., Arcadia -4% FY2025, Q4 -26%), offset by operating expense cuts (Arcadia -15% FY, Mueller +24.4% op income YoY), with outliers like Mueller's record +10.9% sales and +26.5% net income. Critical developments: Mueller's 2030 plan targeting $1.5B op income, Arcadia's terminated deal and $2.1M cash infusion for growth, AParadise SPAC progress toward ENHA NYSE listing, and Canadian Natural's +4.5% proved reserves to 15,910 MMBOE. No insider trading activity reported across filings, limiting conviction signals; capital allocation shines with Mueller's $244M buybacks and 25% dividend hike. Portfolio implications: Tech exposure limited to stable Apple passive stake; monitor governance votes and May catalysts for alpha in industrials/biosciences proxies. Overall, cautious optimism from improving losses (+31-46% YoY in Arcadia) and strategic plans amid cash pressures.

7 high priority 6 medium 13 total filings